Mucopolysaccharidosis type IX, or Natowicz syndrome, is an ultra-rare lysosomal disease caused by biallelic variants in HYAL1. Hyaluronidase-1 deficiency leads to hyaluronan accumulation and primarily affects periarticular tissues, with a predominant musculoskeletal phenotype.
Mucopolysaccharidosis type IX (MPS IX)
Mucopolysaccharidosis type IX (MPS IX), also known as hyaluronidase deficiency, is an extremely rare autosomal recessive lysosomal storage disorder caused by biallelic variants in HYAL1. Reduced or absent hyaluronidase-1 activity leads to the accumulation of hyaluronan or hyaluronic acid, particularly in periarticular tissues.
HYAL1 encodes hyaluronidase-1, a lysosomal enzyme that degrades hyaluronan, an essential glycosaminoglycan of the extracellular matrix, cartilage, and synovial fluid. Loss-of-function of this enzyme results in hyaluronan accumulation and a predominantly musculoskeletal phenotype.
Symptoms
Symptoms usually begin in childhood and include soft periarticular masses or nodules, recurrent joint inflammation and pain, proliferative synovitis, and in some patients, short stature or mild craniofacial features. Unlike other mucopolysaccharidoses, it is not usually associated with neurodegeneration or severe multiple dyostosis, and cognitive development is usually preserved.
Disease management
Currently, there is no curative treatment or approved enzyme replacement therapy for MPS IX. Management is symptomatic and includes pain and inflammation control, rehabilitation, follow-up by rheumatology and traumatology, and surgery for periarticular lesions when indicated.
Genes analyzed
Bibliography
Kiykim E, Barut K, Cansever MS, et al. Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis. JIMD Rep. 2016;25:21-24.
Fink SP, Triggs-Raine B. Genetic Deficiencies of Hyaluronan Degradation. Cells. 2024;13(14):1203.
